Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients
Tectonic Therapeutic (NASDAQ: TECX) said it completed enrollment in its 24-week APEX Phase 2 trial of TX45 for pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF). The trial enrolled 191 patients in 14 countries, with ~72% in CpcPH patients (PVR >3 WU). Topline results are expected in early Q1 2027.
Enrollment completion de-risks trial execution and sets a clear catalyst window for TX45 topline results.
Tectonic says it completed enrollment of 191 patients in its APEX 24-week Phase 2 TX45 trial for PH-HFpEF, with topline expected early Q1 2027.
Near-term sentiment support; larger repricing likely into early Q1 2027 topline depending on PVR endpoint results.
Background
APEX is a 24-week, randomized, double-blind, placebo-controlled Phase 2 proof-of-concept trial of TX45 in PH-HFpEF, enriched for the more severe CpcPH subtype with PVR>3 WU.
Why it matters
Full enrollment (191 patients; 137 in CpcPH with PVR>3 WU) reduces execution risk and clarifies the next major event: TX45 topline results in early Q1 2027 for the primary PVR endpoint.
Market relevance
This is a concrete clinical-development milestone with a defined future catalyst window, but it does not yet provide efficacy or safety outcomes.
Market effects
Adds incremental evidence of ongoing development in Group 2 PH (PH-HFpEF) where no approved therapies exist, supporting investor appetite for GPCR-modulating biologics.
No specific regional market impact beyond global trial execution across 14 countries.
Global, randomized, double-blind trial progress may influence broader expectations for PH-HFpEF drug development timelines.
Alternative perspectives
Enrollment completion can be largely procedural; without interim efficacy/safety signals, the market may discount the news until topline data.
Baseline characteristics are described as preliminary/subject to change, and the primary endpoint is change in PVR in the PVR>3 WU population—trial success hinges on that specific subgroup response.
Key entities
- companyTectonic Therapeutic, Inc.
Clinical-stage biotech developing TX45 for PH-HFpEF; completed enrollment in the APEX Phase 2 trial.
- product_candidateTX45
Long-acting Fc-relaxin fusion protein activating RXFP1; being tested in PH-HFpEF under APEX Phase 2.
- clinical_trialAPEX Phase 2 trial
24-week, randomized, double-blind, placebo-controlled trial with monthly vs every-other-week TX45 dosing and placebo; primary endpoint is PVR change in PVR>3 WU population.
